Home     Font Size: 1  2  3    Send to a Friend       search

2008 News Archive

Morphotek, Inc. Announces Initiation of Farletuzumab Phase II Study in Platinum-Resistant Ovarian Cancer

December 2, 2008

About MorphotekContact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comJudee Shuler Eisai Corporation of North America...

+ Read the Article

Morphotek, Inc. Receives Additional $1.6M in Funding from The U.S. Department of Defense to Develop Therapeutic Antibodies Against Microbial Bioweapons

November 20, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comJudee Shuler Eisai Corporation of North...

+ Read the Article

Morphotek,® Inc. Expands its Phase II Trial Site Selections in The European Union

August 26, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comJudee Shuler Eisai Corporation of North America...

+ Read the Article

Morphotek Announces Collaboration to Facilitate Development of Human Monocolonal Antibodies for the Treatment or Prophylaxis of Infectious Disease

May 21, 2008

Contact: Nicholas C. Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Corporation of North America...

+ Read the Article

European Regulatory Agency Grants Orphan Status to Morphotek's Farletuzumab and MORAb-009

April 16, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Corporation of North America 201-746-2241...

+ Read the Article
Go to Page: 1 2

Results per page   10  25  50



©2005 Morphotek Inc. | 210 Welsh Pool Road | Exton, PA 19341 | (610) 423-6100                        Privacy Policy | Site Map | Contact Us